Pharma BD Deal Intelligence
Novartis Vanrafia (atrasentan) Phase III ALIGN final data support slowing of kidney function decline in IgA nephropathy: eGFR difference vs placebo…
Novartis finalized the Chinook Therapeutics acquisition in a deal worth up to $3.5 billion, adding two Phase 3 assets for IgA nephropathy to significantly…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis acquired Chinook Therapeutics for up to $3.5 billion ($40.00 per share upfront plus $4.00 per share contingent value right), gaining atrasentan and zigakibart (BION-1301), two late-stage assets for IgA nephropathy (IgAN) and other kidney diseases.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chinook Therapeutics Inc. (this deal) | 2023 | $3.5B | 78 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2023 deals · Novartis AG deals · Nephrology deals